Literature DB >> 24613903

Effect of intensity modulated radiotherapy combined with s-1-based chemotherapy in locally advanced gastric cancer patients.

Jian-Bin Hu1, Xiao-Nan Sun, Ben-Xing Gu, Qi Wang, Wen-Xian Hu.   

Abstract

BACKGROUND: The optimal radiotherapy technique and combination with systemic therapy in locally advanced gastric cancer patients are far from being resolved despite the fact that radiochemotherapy is becoming more attractive in contemporary clinical practice. PATIENTS AND METHODS: 40 patients with locally advanced gastric cancer received intensity-modulated radiotherapy (IMRT) at a dosage of 45-50.4 Gy concurrent with chemotherapy using S-1 solely or with a combination of oxaliplatin. Surgery was recommended for those who were evaluated as resectable. Sequential chemotherapy with various regimens was adopted based on the efficacy and tolerance of radiochemotherapy.
RESULTS: The overall response rate was 75% according to Response Evaluation Criteria in Solid Tumors and Japanese Gastric Cancer Association criteria. 24 finally underwent surgery, with 22 (91.7%) receiving an R0 resection (resection for cure or complete remission). The overall pathological response rate was 37.5% (9/24). Patients receiving an R0 resection had a higher 2-year overall survival rate (64.7 vs. 16.2%, p = 0.001) and local relapse-free survival rate (90.2 vs. 29.3%, p = 0.000), while there was no difference in distant metastasis-free survival rate (66.1 and 48.1% p = 0.231). Hematological and gastrointestinal toxicities of grade 1 or grade 2 were relatively common.
CONCLUSION: The high rate of R0 resections and low rate of locoregional recurrence suggest that IMRT combined with S-1-based chemotherapy is an effective treatment for locally advanced gastric cancer patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24613903     DOI: 10.1159/000358164

Source DB:  PubMed          Journal:  Oncol Res Treat        ISSN: 2296-5270            Impact factor:   2.825


  6 in total

1.  Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.

Authors:  Mi Sun Kim; Joon Seok Lim; Woo Jin Hyung; Yong Chan Lee; Sun Young Rha; Ki Chang Keum; Woong Sub Koom
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

2.  Observational Study Comparing Efficacy and Safety between Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy for Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer.

Authors:  Yung-Sung Yeh; Ming-Yii Huang; Cheng-Jen Ma; Ching-Wen Huang; Hsiang-Lin Tsai; Yen-Cheng Chen; Ching-Chun Li; Fang-Jung Yu; Hsiang-Yao Shih; Jaw-Yuan Wang
Journal:  J Oncol       Date:  2020-09-07       Impact factor: 4.375

3.  Evaluation of Multislice Spiral Computed Tomography Perfusion Imaging for the Efficacy of Preoperative Concurrent Chemoradiotherapy in Middle-aged and Elderly Patients with Locally Advanced Gastric Cancer.

Authors:  Jian-Xiao Liang; Xiu-Juan Bi; Xiao-Mei Li; Zhen-Li Gao; Feng Suo; En-Gang Cui; Hong-Fu Li; Hai-Lian Lv
Journal:  Med Sci Monit       Date:  2018-01-12

Review 4.  Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives.

Authors:  A Schernberg; E Rivin Del Campo; B Rousseau; O Matzinger; M Loi; P Maingon; F Huguet
Journal:  Clin Transl Radiat Oncol       Date:  2018-03-13

5.  Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.

Authors:  Fuli Wang; Aizhong Qu; Yinping Sun; Jifeng Zhang; Benzun Wei; Yong Cui; Xiao Liu; Wei Tian; Yan Li
Journal:  Br J Radiol       Date:  2021-07-14       Impact factor: 3.629

6.  Comparison between Heat-Clearing Medicine and Antirheumatic Medicine in Treatment of Gastric Cancer Based on Network Pharmacology, Molecular Docking, and Tumor Immune Infiltration Analysis.

Authors:  Jiamin Xu; Fuqin Kang; Wei Wang; Shujun Liu; Jianhui Xie; Xiaobo Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-11       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.